| Host: | CHO cells |
| Note: | STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | Recombinant-MERS Nucleocapsid protein-protein was developed from cho cells. For use in research applications. |
| Conjugation: | Unconjugated |
| Formulation: | Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: | Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: | The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunogen Region: | RBD |
| Immunogen: | DNA sequence encoding the receptor binding domain of MERS-CoV Nucleoprotein including a C-terminal His tag was expressed in CHO Cells. NA |
| Background | Recombinant MERS-CoV Nucleocapsid is a protein consisting of amino acid residues [1-413], due to glycosylation migrates as an approximately 46 kDa protein on SDS-PAGE. |
Information sourced from Uniprot.org